title: Technology evaluation: FluINsure, ID Biomedical.
abstract: ID Biomedical (formerly Intellivax International) is developing a trivalent nasal influenza vaccine, FluINsure, for the potential treatment of influenza. The vaccine is currently in phase II clinical trials.
authors.affiliation: Baylor College of Medicine, Department of Pediatrics, Molecular Virology and Microbiology, BCM-280, Houston, TX 77030, USA. florm@bcm.tmc.edu
authors.forename: Flor M
authors.initials: FM
authors.lastname: Munoz
mesh_terms: D000281:Administration, Intranasal; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007252:Influenza Vaccines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D007251:Influenza, Human / Q000401:mortality / Q000517:prevention & control*; D010330:Patents as Topic; D013329:Structure-Activity Relationship
chemical_list: D007252:Influenza Vaccines